Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus (IPV) conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus (HPV). The IPV conference is scheduled to take place in Seattle from August 21st to 25th. Additionally, a new U.S. patent was issued earlier this year for Trovagene's non-invasive HPV assay, and the Company continues to pursue its global partnering strategy to commercialize this novel technology.
Presentations at the 29th IPV Conference
Title: Evaluation of Two Urine-Based HPV Assays In Comparison to Cervical HPV Detection and High-Grade CIN Among Women Attending a Colposcopy Clinic
Abstract Number: CS.PD01.08
Date: Friday, August 22, 2014
Session: Clinical Science Poster Discussion 4:15pm to 5:15pm PDT
Presenter: Vikrant Sahasrabuddhe, M.D., Ph.D., National Cancer Institute, Bethesda, MD.
Title: A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women
Abstract Number: CS.PP05.11
Date: Saturday, August 23, 2014 Session: Clinical Science Poster Presentation 1:45pm to 3:45pm PDT
Presenter: Virginia Senkomago, Ph.D., Department of Epidemiology, University of North Carolina at Chapel Hill
"We look forward to the clinical data presentations at the IPV conference, and to advancing our HPV program," stated Dr. Mark Erlander, Ph.D., chief scientific officer of Trovagene. "The studies to be presented continue to evaluate the potential of our HPV assay as a viable alternative to traditional HPV testing from a cervical sample."
In addition, earlier this year, the U.S. Patent and Trademark Office issued U.S. Patent No. 8,642,261, titled "Genetic Marker for Detection of Human Papillomavirus". The invention provides compositions and methods for the differential detection of high risk forms of HPV from a urine sample provided by a patient. Detection of high risk forms of HPV identify individuals at risk of developing, or in the early stages of, cervical carcinoma. The invention claims certain primers and probes that specifically recognize and bind sequences within the E1 gene of HPV.